跳至主要内容
临床试验/NCT04390412
NCT04390412Unknown1 期

Assessment of Adding Low Dose Pulmonary Radiotherapy to the National Protocol of COVID-19 Management: A Pilot Trial

Shahid Beheshti University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2020年5月4日最近更新:
适应症
干预措施

试验速览

阶段
1 期
入组人数
5
试验地点
1
主要终点
Change from baseline blood oxygenation

研究概览

简要总结

Moderate to severe cases of SARS-associated ARDS based on inclusion/ exclusion criteria and the decision made in multi- disciplinary team are treated with 0.5 Gy whole lung radiation.

详细描述

SARS-associated ARDS (acute respiratory distress syndrome) is the most fatal outcome of COVID-19 systemic infection. To overcome the uncontrolled inflammation leading to ARDS and respiratory failure, several drugs have been investigated in this situation with the most promising results coming from anti-inflammatory agents that directly or indirectly inhibit IL-6 and its counterparts of inflammation.

Low dose radiation, as opposed to high dose, has documented anti-inflammatory effects that are exercised through various mechanisms including decrease in pro-inflammatory cytokines such as IL-6.

In this pilot clinical trial, the patients are carefully selected according to inclusion /exclusion criteria and the clinical judgement of the multi- disciplinary team.Their diagnostic CT scan will be used to plan an AP/ PA radiotherapy treatment to both lungs and the set-up positioning information is obtained from anatomical landmarks. The patient will be referred for a fraction of 0.5 Gy to both lungs and for the next 28 days the clinical para-clinical and radiologic variables of disease severity will be monitored closely. Should the patient's clinical course indicate and the multi- disciplinary team approves, they may be subjected to another fraction of 0.5 Gy to a maximum of 1 Gy in two fractions at least 72 hours apart. All the patients will also receive the standard national protocol of COVID-19 management.

A total of 5 patients will be enrolled in the RT arm, providing favourable results seen in the first set of patients, the team will decide on recruiting a larger number for a phase II clinical trial.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Confirmed COVID-19 diagnosis ( PCR or serologic or radiographic)
  • •Presence of pulmonary involvement ( defined by P/F ratio or NIV need)
  • •Less than 3 days since the onset of ARDS
  • •Age > 60 years
  • •↑ IL-6 ( if available)

排除标准

  • •Lack of informed consent
  • •Inability to transfer to the radiation unit
  • •Hemodynamic instability
  • •Septic shock and organ dysfunction
  • •Severe ARDS P/F ratio ≤ 100 mmHg
  • •History of cardiac failure
  • •Contraindications to radiation

研究组 & 干预措施

Low Dose Radiotherapy

Experimental

0.5 Gy radiation to both lungs in an AP/PA fashion

干预措施: Low Dose Radiotherapy (Radiation)

结局指标

主要结局

Change from baseline blood oxygenation

时间窗: 28 days

O2 saturation

Number of Hospital stay days

时间窗: 28 days

Total days the patient is admitted to hospital

Number of ICU stay days

时间窗: 28 days

Total days the patient is admitted to ICU

Number of intubation events

时间窗: 28 days

Total number of intubations performed after the treatment

次要结局

  • IL-6(Day 5)
  • WBC(28 days)
  • Platelets(28 days)
  • CRP(Day 5)
  • CRP(Day 1)
  • CRP(Day 2)
  • CRP(Day 3)
  • CRP(Day 4)
  • IL-6(Day 1)
  • IL-6(Day 2)
  • IL-6(Day 3)
  • IL-6(Day 4)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验